Tumor Necrosis Factor-alpha (TNF-α) −238 G/A Polymorphism Is Associated with the Treatment Resistance and Attempted Suicide in Schizophrenia

References

• Arslan S, Karakılıç GKB. 2001. İçgörünün üç bileşenini değerlendirme ölçeği: güvenilirlikve geçerlik çalışması. Türkiye’de Psikiyatri. 3:17–24.
   Google Scholar
• Avramopoulos D, Pearce BD, McGrath J, Wolyniec P, Wang R, Eckart N, Hatzimanolis A, Goes FS, Nestadt G, Mulle J. 2015. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One. 10(3):e0116696.
   PubMed Web of Science ®Google Scholar
• Aytac HM, Oyaci Y, Yazar MS, Erol A, Pehlivan S. 2020. Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder. J Clin Neurosci. 78:264–68.
   PubMed Web of Science ®Google Scholar
• Bani-Fatemi A, Jeremian R, Wang KZ, Silveira J, Zai C, Kolla NJ, … De Luca V. 2018. Epigenome-wide association study of suicide attempt in schizophrenia. J Psychiatr Res. 104:192–97.
   PubMed Web of Science ®Google Scholar
• Black C, Miller BJ. 2015. Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry. 78(1):28–37.
   PubMed Web of Science ®Google Scholar
• Brundin L, Bryleva EY, Rajamani KT. 2017. Role of inflammation in suicide: from mechanisms to treatment. Neuropsychopharmacology. 42(1):271.
   PubMed Web of Science ®Google Scholar
• Çorapçıoğlu A, Aydemir Ö, Yıldız M, Esen A, Köroğlu E. 1999. DSM-IV Eksen I Bozuklukları (SCID-I) için yapılandırılmış klinik görüşme kullanım kılavuzu (SCIDI). Ankara: Hekimler yayın birliği.
   Google Scholar
• Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. 2010. Suicide in schizophrenia. Expert Rev Neurother. 10(7):1153–64.
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. 2001. Management of treatment resistance in schizophrenia. Biol Psychiatry. 50(11):898–911.
   PubMed Web of Science ®Google Scholar
• David AS. 1990. Insight and psychosis. Br J Psychiatry. 156:798–808.
   PubMed Web of Science ®Google Scholar
• Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang Y-P. 2013. Lack of association of IL-6 (− 174 G> C) and TNF-α (− 238 G> A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine. 61(2):455–58.
   PubMed Web of Science ®Google Scholar
• Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, … Zhang X. 2004. No association between the promoter variants of tumor necrosis factor alpha (TNF-α) and schizophrenia in Chinese Han population. Neurosci Lett. 366(2):139–43.
   PubMed Web of Science ®Google Scholar
• Erol N, Kılıç C, Ulusoy M, Kececi M. 1998. Mental health profile in Turkey: a main report. Ankara: Turkish Republic, Ministry of Health; p. 77–93.
   Google Scholar
• Fawzi MH, Fawzi MM, Fawzi MM, Said NS. 2011. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 190(1):91–97.
   PubMed Web of Science ®Google Scholar
• Fineberg AM, Ellman LM. 2013. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 73(10):951–66.
   PubMed Web of Science ®Google Scholar
• Fuller-Thomson E, Hollister B. 2016. Schizophrenia and suicide attempts: findings from a representative community-based Canadian sample. Schizophr Res Treatment. 2016:1–11.
   Web of Science ®Google Scholar
• Guy W. 1976. bEarly clinical drug evaluation unit (ECDEU) asssment manual psychopharmology. Revised. Rockville, National Institude of Mental. Health US. 76:217–22.
   Google Scholar
• Handoko HY, Nancarrow DJ, Hayward NK, Ohaeri JU, Aghanwa H, McGrath JJ, … Nertney DA. 2003. Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia‐Pacific region. Am J Med Genet Part B. 121(1):1–6.
   Google Scholar
• Hanninen K, Katila H, Rontu R, Mattila KM, Hurme M, Lehtimaki T. 2005. Tumor necrosis factor-alpha –G308A polymorphism in schizophrenia in a Finnish population. Neurosci Lett. 385(1):76–81.
   PubMed Web of Science ®Google Scholar
• Hor K, Taylor M. 2010. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 24(4_suppl):81–90.
   PubMedGoogle Scholar
• Huang L-C, Liu C-M, Hwu H-G. 2008. A negative study of the association between tumor necrosis factor alpha-308G/A polymorphism and schizophrenia among Taiwanese patients. Taiwanese J Psychiatry. 22:141–7
   Google Scholar
• Inoubli O, Jemli A, Ben Fredj S, Mechri A, Gaha L, Bel Hadj JB. 2018. Haplotypes of tnfα/β genes associated with sex-specific paranoid schizophrenic risk in Tunisian population. Dis Markers. 2018:1–12.
   Web of Science ®Google Scholar
• Jemli A, Eshili A, Trifa F, Mechri A, Zaafrane F, Gaha L, … Tensaout BBHJ. 2017. Association of the IFN-γ (+ 874A/T) genetic polymorphism with paranoid schizophrenia in Tunisian population. Immunol Invest. 46(2):159–71.
   PubMed Web of Science ®Google Scholar
• Kadasah S, Arfin M, Rizvi S, Al-Asmari M, Al-Asmari A. 2017. Tumor necrosis factor-α and-β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia. Neuropsychiatr Dis Treat. 13:1081.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–76.
   PubMed Web of Science ®Google Scholar
• Kostakoğlu A, Batur S, Tiryaki A, Göğüş A. 1999. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi. 14(44):23–32.
   Web of Science ®Google Scholar
• Lahdelma L, Ahokas A, Andersson LC, Suvisaari J, Hovatta I, Huttunen MO, Koskimies S. 2001. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol. 21(1):4–7.
   PubMed Web of Science ®Google Scholar
• Lang X, Trihn TH, Wu HE, Tong Y, Xiu M, Zhang XY. 2020. Association between TNF-alpha polymorphism and the age of first suicide attempt in chronic patients with schizophrenia. Aging. 12(2):1433–45.
   PubMedGoogle Scholar
• Lee H-Y, Kim Y-K. 2010. Effect of TGF-β1 polymorphism on the susceptibility to schizophrenia and treatment response to atypical antipsychotic agent. Acta Neuropsychiatr. 22(4):174–79.
   PubMed Web of Science ®Google Scholar
• Lee W-C, Wang L-Y. 2008. Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol. 167(1):86–89.
   PubMed Web of Science ®Google Scholar
• Meyer U, Schwarz MJ, Muller N. 2011. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 132(1):96–110.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Goldsmith DR. 2019. Inflammatory biomarkers in schizophrenia: implications for heterogeneity and neurobiology. Biomarkers Neuropsychiatry. 1:100006.
   Google Scholar
• Momtazmanesh S, Zare-Shahabadi A, Rezaei N 2019. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 10(892). doi:https://doi.org/10.3389/fpsyt.2019.00892
   Google Scholar
• Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, Dazzan P, Zunszain PA, Morgan C, Murray RM. 2015. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull. 41(5):1162–70.
   PubMed Web of Science ®Google Scholar
• Müller N, Myint A-M, Krause D, Weidinger E, Schwarz MJ. 2013. Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 42:146–53.
   PubMed Web of Science ®Google Scholar
• Na K-S, Kim Y-K. 2007. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology. 56(2–3):55–63.
   PubMed Web of Science ®Google Scholar
• Nishimon S, Ohnuma T, Takebayashi Y, Katsuta N, Takeda M, Nakamura T, Sannohe T, Higashiyama R, Kimoto A, Shibata N. 2017. High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 76:145–54.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Serretti A, Artioli P, Kim T-S, Kim -J-J, Lee C-U, Lee C, Paik I-H, Lee C. 2006. Interaction analysis between 5-HTTLPR and TNFA− 238/− 308 polymorphisms in schizophrenia. J Neural Transm. 113(7):887–97.
   PubMed Web of Science ®Google Scholar
• Pandey GN, Rizavi HS, Bhaumik R, Ren X. 2019. Innate immunity in the postmortem brain of depressed and suicide subjects: role of toll-like receptors. Brain Behav Immun. 75:101–11.
   PubMed Web of Science ®Google Scholar
• Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K, Kowalski J, Borkowska P, Kowalski J. 2013. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a polish population. J Neuropsychiatry Clin Neurosci. 25(1):72–82.
   PubMed Web of Science ®Google Scholar
• Riedel M, Kronig H, Schwarz MJ, Engel RR, Kuhn KU, Sikorski C, Muller N, Müller H-J, Müller N, Riedel M. 2002. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci. 252(5):232–34.
   PubMed Web of Science ®Google Scholar
• Shirts BH, Wood J, Yolken RH, Nimgaonkar VL. 2006. Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. Schizophr Res. 88(1–3):235–44.
   PubMed Web of Science ®Google Scholar
• Sidhom O, Laadhar L, Zitouni M, Ben Alaya N, Rafrafi R, Kallel-Sellami M, Lahmar H, El Hechmi Z, Makni S. 2012. Spectrum of autoantibodies in Tunisian psychiatric inpatients. Immunol Invest. 41(5):538–49.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 49(8):624–29.
   PubMed Web of Science ®Google Scholar
• Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein H-G, Bogerts B. 2008. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 42(2):151–57.
   PubMed Web of Science ®Google Scholar
• Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J. 2014. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 41:23–32.
   PubMed Web of Science ®Google Scholar
• Suchanek-Raif R, Raif P, Kowalczyk M, Paul-Samojedny M, Kucia K, Merk W, Kowalski J. 2018. Promoter polymorphisms of TNF-α gene as a risk factor for schizophrenia. Arch Med Res. 49(4):248–54.
   PubMed Web of Science ®Google Scholar
• Tsai S-J, Hong C-J, Yu YWY, Lin C-H, Liu -L-L. 2003. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res. 65(1):27–32.
   PubMed Web of Science ®Google Scholar
• Turgay T, Aydeniz A, Pehlivan S, Pehlivan M, Altındağ Ö, Gürsoy S. 2017. Influence of promoter region of TNF-α gene polymorphisms on anti-TNF treatment in rheumatoid arthritis: preliminary report. Pam Med J. 10(3):216–20.
   Google Scholar
• Watanabe Y, Muratake T, Kaneko N, Fukui N, Nara Y, Someya T. 2007. No association between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiatry Res. 153(1):1–6.
   PubMed Web of Science ®Google Scholar
• Williams JR. 2008. The Declaration of Helsinki and public health. Bull World Health Organ. 86:650–52.
   PubMed Web of Science ®Google Scholar
• Xiu M, Zhang G, Chen N, Chen S, Tan Y, Yin G, Teixeira AL, Ning Y, Huang X, Teixeira AL. 2019. The TNF-alpha gene− 1031T> C polymorphism is associated with onset age but not with risk of schizophrenia in a Chinese population. Neuropsychology. 33(4):482.
   PubMed Web of Science ®Google Scholar
• Zai G, Muller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL. 2006. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl). 188(2):171–82.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. 2004. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 65(7):940–47.
   PubMed Web of Science ®Google Scholar
• Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, Zhang X, Zhao J. 2018. Altered serum tumor necrosis factor and interleukin-1β in first-episode drug-naive and chronic schizophrenia. Front Neurosci. 12:296.
   PubMed Web of Science ®Google Scholar